These mainly include signaling, cytoskeleton and vesicular-associated proteins. Interestingly, Src also phosphorylated a cluster of tyrosine kinases, ie the receptors Met and EphA2, the cytoplasmic tyrosine kinase Fak and pseudo-tyrosine kinase SgK223, which were required for its invasive activity. Similar results were obtained with the metastatic Colo205 CRC cells that exhibit high endogenous Src activity. We concluded that Src uses a tyrosine kinases network to promote its invasive activity in CRC and this implicates a reverse signaling via tyrosine kinase receptors. Targeting these tyrosine kinases may be of significant therapeutic value in this cancer.
INTRODUCTION
The non receptor tyrosine kinase Src plays important roles in cell proliferation, survival and migration induced by extracellular stimuli including growth factors and integrins (1) . It also shows oncogenic activity when deregulated, a situation originally found with vSrc, the transforming product of the avian retrovirus RSV (2) . Since then, Src has been reported deregulated in human cancer (3) . Remarkably, elevated kinase activity has been found in more than 80% of CRC as compared to the normal counterpart and this has been associated with a poor clinical outcome (3) . How Src is deregulated in this cancer has not been clearly established yet. An activating mutation has been reported in a minority of advanced tumors, suggesting the existence of alternative mechanisms for kinase deregulation (4) . Accordingly, kinase activation often correlates with protein overexpression (2) . This molecular event is however not sufficient in a normal cellular context as Src is subjected to strict regulation that keeps the enzyme in an inactive form. Therefore, it has been postulated that Src activation additionally implicates alteration of important Src regulators by genetic or epigenetic mechanisms, including the inhibitory C-terminal Src tyrosine kinase Csk (2) .
A large body of evidence points to Src deregulation as an important event for colon tumorigenesis and metastasis (3) . For instance, Src regulates growth, survival and invasion of some CRC cell-lines in vitro (3, 5) . Moreover, it contributes to tumor growth, angiogenesis and metastasis in xenografts nude mouse models (3) . Therefore, Src has become an attractive therapeutic target in this cancer and several small inhibitors are under clinical trials.
Intriguingly, these Src oncogenic signaling have been unraveled only partially. While Src interacts with components of the focal contacts and the adherent junctions for cell migration (2) , substrates important for cellular growth and invasiveness have been poorly described.
MS-based quantitative phosphoproteomics has been a valuable tool to decipher signaling pathways initiated by a given tyrosine kinase (6) . Among these, the Stable Isotope Labeling with Amino acids in Cell culture (SILAC) has been employed for the identification of oncogenic tyrosine kinase signaling such as HER2 (7) and Bcr-Abl (8) . Here we used this approach to address Src oncogenic signaling in advanced CRC cells. By overexpressing Src in SW620 cells, we identified 136 substrates and/or tyrosine phosphorylation-associated proteins. These include proteins with signaling, cytoskeleton and vesicular trafficking functions, which may be important for the high Src invasiveness observed in these cells.
Additionally, we identified a small cluster of tyrosine kinases that mediates this Src oncogenic signaling, uncovering a tyrosine kinases network important for the induction of cellular invasion. Targeting these tyrosine kinases may therefore be of significant value in advanced CRC therapy.
MATERIAL AND METHODS
Reagents. Human Src has been subcloned in pMX-pS-CESAR. Construct expressing Pragmin (a gift of Dr Negishi, Kioto University) and PragminY397F that was generated by mutagenesis have been subcloned into pBABE retroviral vectors. pRETRO-SUPER expressing shRNA used in this study were from TRANSAT (Saint-Priest, France). Targeting sequences inserted in shRNA constructs were GACACTCGGTAGTCTATAC (control), phosphotyrosine immunoaffinity purification (using a mixture of a mixture of 4G10 and pY100 antiboies), and tryptic digests were essentially performed as described in (11) Biochemistry. Immunoprecipitation, Western blotting and siRNA transfections were performed as described in (44) . Imunoprecipitates (ip, when indicated) or 20 to 50 µg of proteins of a whole cell lysate were loaded per lane on 9% SDS-PAGE gels and then transferred onto Immobilon membranes (Milllipore) as previously described. Detection was performed using the ECL system (Amersham). Optimal exposure times of membranes were used and protein expression and phosphorylation was quantified using ImageQuant TL software (Molecular Dynamics), and adjusted for background noise and protein loading.
RESULTS

Src promotes growth and invasiveness of the SW620 CRC cells.
We first transduced wild-type Src retrovirally in the metastatic CRC SW620 cells that exhibit a moderate level of endogenous Src as compared to the metastatic Colo205 cells (9) . A >5 fold increase in Src protein level was obtained ( Fig. S1 ). While Src moderately increased cell motility (Fig. 1D , left panel), it induced remarkable cell invasiveness (Fig. 1D, right panel) . This cellular activity was still dependent upon Src activity as it was inhibited by the Src-like inhibitor SU6656 (10) (Fig. 1D, right panel) . This data supports the hypothesis that the induction of the Src level is sufficient to induce its oncogenic activity even at late stage of tumorigenesis Quantitative Src phosphoproteomics in CRC cells.
We next sought Src substrates important for oncogenic signaling by quantitative phosphoproteomics using the SILAC approach. SW620-Src cells were labeled with "heavy" 13 C 6 15 N 4 -Arg-and 13 C 6 15 N 2 -Lys-containing medium while SW620 cells were cultured in "light" normal conditions. Cell lysates were next combined, and phosphotyrosine-containing proteins were purified using anti-phosphotyrosine antibodies. Proteins were separated by SDS/PAGE, digested with trypsin, and subjected to liquid chromatography-tandem MS (11).
Quantification was made from the relative intensities of Arg/Lys labeled tryptic peptides.
With this approach, we obtained 467 proteins, 136 of which exhibiting increased, and 13 reduced, tyrosine phosphorylation, upon Src expression ( Fig. 2B and Supplementary Table   S1 ). The small number of reduced phosphorylations was attributed to the cellular treatment of the tyrosine phosphatases inhibitor orthovanadate performed shortly before lysis in order to increase tyrosine phosphorylation content. Src-induced phosphorylation was next confirmed biochemically for 32/35 of them ( Fig. 3 and 4A Table S2 ). Of some note are the CDCP1/PKCδ transmembrane signaling complex involved in survival (12) , the E-cadherin/catenins complexes in mesenchyme induction and cell motility (2) , and proteins of the ERM family in cell invasion (13) . Additionally, Src targets the Wave2 and the alpha6/beta4 integrin complexes, recently identified as novel players of epithelial cell motility/invasion (14, 15) .
We also noticed a subgroup of signaling proteins that regulate the small GTPases of the Rho family, and which may modulate actinic cytoskeleton occurring during cell invasion (13) .
These include the Rho GAP ARAP1, 3 and p200 Rho GAP, and the Rho GEF Vav2 and FGD5, which has not been previously identified as a Src substrate. Unexpectedly, we found a third group of 23 Src targets with vesicular trafficking functions (supplementary Table S2 ).
This was exemplified with components of the COPII complex of the secretory pathway (16) and VHS-containing proteins (Hrs and Tom1L1), involved in transmembrane proteins trafficking/signaling (17) .
Src phosphorylates a cluster of tyrosine kinases important for cell invasiveness.
The SILAC analysis confirmed a 6 fold increase in Src expression showing accuracy of the method, but it additionally identified a cluster of 7 protein tyrosine kinases and pseudotyrosine kinases as potential Src substrates (Table 1 ). This included the receptors Met, EphA2
and EphB2, and the cytoplasmic tyrosine kinases Fak and Syk and pseudokinases SgK223 and SgK269. Increased tyrosine phosphorylation was confirmed for 5 of them biochemically, ie Met, EphA2, Fak, Syk and SgK223 (Fig. 4A) , and this correlated with a Src complex formation (not shown). Similar results were obtained from cells that were not treated with the phosphatase inhibitor orthovanadate, indicating that these phosphorylations were specific to Src expression ( Supplementary Fig. S2A ). We next investigated their role in Src-induced tyrosine phosphorylation. To this end, respective tyrosine kinase was inactivated by stably expressing a shRNA leading to >50% reduction of both mRNA (not shown) and protein levels ( Fig. S2B ). Therefore Src may use these TyrK activities to induce maximal phosphorylation in these CRC cells.
Surprisingly, Src specific activity was also reduced in these cells with inactive Met, EphA2, Syk and SgK223, suggesting the existence of interplay between Src and these TyrK for signaling (Fig. 4C) . The function for these kinases was next evaluated on Src oncogenic activity. We found that Src-induced anchorage-independent cell growth was strongly inhibited in all cell-lines, except for Met (Fig. 4D) . However, none of them had a significant role in Src-induced cell proliferation ( Supplementary Fig. S3 ), indicating that these TyrK may impact on survival signaling rather than cell-cycle progression, the later being probably ensured by phosphorylation of direct Src substrates.
The role for these TyrK was next evaluated on Src-induced invasiveness. We found that this cellular activity was strongly inhibited in all cell-lines with down-regulated tyrosine kinases, except Syk (Fig. 5A, left panel) . Similar results were obtained from SW620-Src cells that were transiently transfected with specific siRNA targeting Met, EphA2 and Fak, indicating that these inhibitory effects were not due to off-targets and/or long-term depletion of these kinases ( Supplementary Fig. S4C and S4D ). In contrast, they had a low impact on the residual invasiveness of SW620 cells, confirming that their role is tightly related to Src activity (Fig S4A and B) . (Supplementary Fig. S3 ). This compound may therefore target an additional kinase important for cellular proliferation to be identified.
Since very few information is available on SgK223, we wished to address its invasive function in more details. To this end, the rat ortholog Pragmin was reintroduced in SW620-Src cells with reduced Sgk223, which was not targeted with the used shRNA sequence.
Pragmin largely restored Src invasive activity, confirming a specific function for SgK223 in this signaling process ( Fig. 5B and 5C ). Whether this uncovered function was regulated by Src was next investigated. The phosphosite data base http://www.phosphosite.org revealed that SgK223 was frequently phosphorylated on Tyr413. Accordingly, we found that Src induced a robust phosphorylation of Pragmin in these cells, unlike PragminY391F, in which the corresponding Tyr413 present in Pragmin was replaced by Phe (Fig. 5B) . At the functional level, PragminY391F had a reduced rescuing effect in these cells (Fig. 5C ). This set of data strongly suggested Src invasive signaling implicates phosphorylation of SgK223 on Tyr413 in advanced CRC cells.
Finally, we wished to confirm these data in cells expressing high endogenous Src, with the example of the metastatic CRC cell-line Colo205. As observed with SW620-Src, these cells required a Src-like activity to induce cellular invasion (Fig. 6D) . We found that the tyrosine kinases Met, EphA2, Fak, Syk were also phosphorylated in a Src-like dependent manner, as suggested with the Src-like inhibitors SU6656, PP1 and PP2 (Fig. 6A) . The variable effect of SU6656 and PP1 on these biochemical events were attributed to their capacity to target distinct pools of Src present in these cells rather than the targeting of additional kinases (not shown). SgK223 protein phosphorylation could not be assessed in these cells. This may probably due to the moderate efficacy of our antibodies and the low level of the expressed protein as observed on its mRNA level (not shown). At the functional level, all these phosphorylated TyrK, but not Syk, were required for cell invasion: downregulation of respective kinases (Fig. 6B) with the same shRNA strategy gave strong inhibitory effects (Fig. 6D) . Thus, Src uses a similar TyrK network to induce its invasive activity in Colo205 cells, suggesting the existence of a common TyrK signaling network for oncogenic induction in advanced CRC cells. Another important insight from this study relies on the interaction of Src with a cluster of tyrosine kinases required for cell invasion. Src may thus require additional tyrosine kinases to phosphorylate components of the invasive pathway. This cluster comprises the receptors Met and EphA2, previously reported interacting with Src (20, 21) and being implicated in CRC tumorigenesis (22, 23) . Moreover, our functional studies demonstrate that they mediate Src oncogenic activity in agreement with a reverse signaling process operating in these cells.
DISCUSSION
It also includes the cytoplasmic tyrosine kinase Fak, which has been largely implicated in Srcinduced cell motility and invasion (24) . Interestingly, Fak does not impact on the global tyrosine phosphorylation content in contrast to the other members of the cluster, suggesting that either it phosphorylates a discrete group of substrates or it has an adaptor function, as previously reported (24) . More surprisingly is the identification of Syk as a Src substrate in these cancer cells, which is inconsistent with its tumor suppressor role described in breast cancer (25) . Therefore, Syk may have distinct functions dependent on the tumor origin. In supporting this idea, Syk regulates Src-induced tyrosine phosphorylation and anchorageindependent growth of SW620-Src cells. This is further supported with the function recently reported in squamous cell carcinoma of the head and neck (26) . Finally, we show that Src also uses SgK223 for its invasive activity. SgK223 belongs to the 10 % of catalytic-inactive kinases present in the human kinome (27) that nevertheless can have important oncogenic function. This has been first highlighted with the EGF receptor member HER3 in breast cancer. HER3 exhibits a co-receptor function that boosts signaling induced by other receptors of the family (28) . Very few information is however available for SgK223. It belongs to the NFK3 sub-family that also includes SgK269, with unknown functions (27) . Interestingly, SgK223 has been recently identified as an important effector of the small GTPase Rnd2 for Rho-dependent F-actin assembly (29) , which would fit with its pro-invasive activity in CRC cells. While it does not have apparent intrinsic tyrosine kinase activity (not shown), SgK223 strongly impacts on Src-induced tyrosine phosphorylation in cellulo. We thus hypothesize that it regulates Src phosphorylation events important for Rho-dependent signaling. Overall, these results assign an unanticipated role for SgK223 in Src oncogenic signaling and suggest an involvement of this pseudo-kinase in CRC advanced tumorigenesis. 
